Anti-cancer compounds targeting Ral GTPases and methods of using the same

US11964985B2 · kind B2 · utility

Assignees

• The Regents of the University of Colorado, a Body Corporate · US
• INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION · US
• University of Virginia Patent Foundation · US

Inventors

• Dan Theodorescu · Englewood, US
• Michael Fitzpatrick Wempe · Aurora, US
• David Ross · Cary, US
• Samy Meroueh · Carmel, US
• Martin A. Schwartz · Poway, US
• Phillip Reigan · Denver, US

Key dates

• Filing date: May 12, 2020
• Grant date: Apr 23, 2024
• Expiry date: May 12, 2040

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P43/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provides methods of inhibiting the growth or metastasis of a cancer in a mammal by inhibiting a Ral GTPase in the mammal. The invention also provides small molecule inhibitors of Ral GTPases useful in the methods of the invention and pharmaceutical compositions containing the therapeutically effective compounds of the invention, and methods of using the same.